tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2020 Apr 13. pii: AAC.02561-19. doi: 10.1128/AAC.02561-19. [Epub ahead of print]
Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
Nguyen CT[SUP]1[/SUP], Suzuki S[SUP]1[/SUP], Itoh Y[SUP]2[/SUP], Ishigaki H[SUP]1[/SUP], Nakayama M[SUP]1[/SUP], Hayashi K[SUP]1,[/SUP][SUP]3[/SUP], Matsuno K[SUP]4,[/SUP][SUP]5[/SUP], Okamatsu M[SUP]4[/SUP], Sakoda Y[SUP]4,[/SUP][SUP]5[/SUP], Kida H[SUP]6[/SUP], Ogasawara K[SUP]1,[/SUP][SUP]7[/SUP].
Author information
Abstract
Attention has been paid to H5N6 highly pathogenic avian influenza virus (HPAIV) because of its heavy burden on the poultry industry and human mortality. Since an influenza A virus carrying N6 neuraminidase (NA) has never spread in humans, the potential for H5N6 HPAIV to cause disease in humans and the efficacy of antiviral drugs against the virus need to be urgently assessed. We used non-human primates to elucidate the pathogenesis of H5N6 HPAIV as well as to determine the efficacy of antiviral drugs against the virus. H5N6 HPAIV infection led to high fever in cynomolgus macaques. The lung injury caused by the virus was severe with diffuse alveolar damage and neutrophil infiltration. In addition, an increase in IFN-α showed an inverse correlation with virus titers during the infection process. Oseltamivir was effective for reducing H5N6 HPAIV propagation, and continuous treatment with peramivir reduced virus propagation and severity of symptoms in the early stage. This study also showed the pathologically severe lung injury states in the cynomolgus macaques infected with H5N6 HPAIV, even in those that received early antiviral drug treatments, indicating the need for close monitoring and the need for further studies on the virus pathogenicity and new antiviral therapies.
Copyright ? 2020 American Society for Microbiology.
PMID:32284377DOI:10.1128/AAC.02561-19
Efficacy of neuraminidase inhibitors against H5N6 highly pathogenic avian influenza virus in a non-human primate model.
Nguyen CT[SUP]1[/SUP], Suzuki S[SUP]1[/SUP], Itoh Y[SUP]2[/SUP], Ishigaki H[SUP]1[/SUP], Nakayama M[SUP]1[/SUP], Hayashi K[SUP]1,[/SUP][SUP]3[/SUP], Matsuno K[SUP]4,[/SUP][SUP]5[/SUP], Okamatsu M[SUP]4[/SUP], Sakoda Y[SUP]4,[/SUP][SUP]5[/SUP], Kida H[SUP]6[/SUP], Ogasawara K[SUP]1,[/SUP][SUP]7[/SUP].
Author information
Abstract
Attention has been paid to H5N6 highly pathogenic avian influenza virus (HPAIV) because of its heavy burden on the poultry industry and human mortality. Since an influenza A virus carrying N6 neuraminidase (NA) has never spread in humans, the potential for H5N6 HPAIV to cause disease in humans and the efficacy of antiviral drugs against the virus need to be urgently assessed. We used non-human primates to elucidate the pathogenesis of H5N6 HPAIV as well as to determine the efficacy of antiviral drugs against the virus. H5N6 HPAIV infection led to high fever in cynomolgus macaques. The lung injury caused by the virus was severe with diffuse alveolar damage and neutrophil infiltration. In addition, an increase in IFN-α showed an inverse correlation with virus titers during the infection process. Oseltamivir was effective for reducing H5N6 HPAIV propagation, and continuous treatment with peramivir reduced virus propagation and severity of symptoms in the early stage. This study also showed the pathologically severe lung injury states in the cynomolgus macaques infected with H5N6 HPAIV, even in those that received early antiviral drug treatments, indicating the need for close monitoring and the need for further studies on the virus pathogenicity and new antiviral therapies.
Copyright ? 2020 American Society for Microbiology.
PMID:32284377DOI:10.1128/AAC.02561-19